上海微创心脉医疗科技（集团）股份有限公司 关于 2025 年度"提质增效重回报"行动方案的半年 度评估报告 为贯彻中央经济工作会议、中央金融工作会议精神，践行"以投资者为本" 的上市公司发展理念，推动上海微创心脉医疗科技（集团）股份有限公司（以下 简称"公司"）持续优化经营、规范治理和积极回报投资者，大力提高公司质量， 助力信心提振、资本市场稳定和经济高质量发展，基于对公司未来发展前景的信 心、对公司价值的认可和切实履行社会责任，公司于 2025 年 3 月 29 日发布了 《2025 年度"提质增效重回报"专项行动方案》，以进一步提升公司经营效率， 强化市场竞争力，保障投资者权益，稳定股价，树立良好的资本市场形象。现对 公司 2025 年度"提质增效重回报"行动方案半年度实施情况及效果进行评估总结， 具体如下： 一、聚焦主动脉及外周血管介入领域，巩固提升核心竞争力 未来，公司将在正常经营的前提下，结合公司经营现状和业务发展规划，继 续坚持为投资者提供持续、稳定的现金分红，给股东带来长期的投资回报。 报告期内，公司实现营业总收入 71,442.98 万元，比上年同期下降 9.24%； 营业成本 22,013. ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a significant price increase in the next 6-12 months [5]. Core Insights - The company reported a revenue of 332 million yuan in Q1 2025, a year-on-year decrease of 7%, and a net profit attributable to shareholders of 130 million yuan, down 30% year-on-year [2]. - The domestic market is facing short-term pressure due to changes in the market environment, leading to adjustments in product pricing and promotional strategies, while the overseas market is expanding rapidly with a sales revenue growth of over 93% year-on-year [3]. - The company has set ambitious growth targets in its employee stock ownership plan, aiming for a net profit of no less than 600 million yuan in 2025, reflecting confidence in future operations [4]. Summary by Sections Performance Overview - In Q1 2025, the company achieved a revenue of 332 million yuan, a decrease of 7% year-on-year, and a net profit of 130 million yuan, down 30% year-on-year [2]. Operational Analysis - The domestic market is under pressure, but the company maintains a leading market share in domestic active artery intervention products and is expanding its market coverage for peripheral vascular intervention products. The overseas market has seen a significant increase in sales, with new registrations in three countries and over 100 total overseas product registrations [3]. Profit Forecast and Valuation - The company is projected to achieve net profits of 606 million yuan, 794 million yuan, and 965 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 21%, 31%, and 22% [5].